TICKERNERD
Menu
INGNHealthcare · Medical Devices

INGN Stock Forecast: Inogen, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$6.86
−5.51% on the day

The 2 Wall Street analysts covering Inogen, Inc. hold a median 12-month price target of $12 — +74.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$182.1M
Ticker Nerd rank
82/ 100
Median analyst target
$12
Analysts covering
2
Revenue$95.1M+3.0% y/y
Operating income−$5.1M
Net income−$3.9M
Free cash flow$1.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
+30.2%
YTD
+2.1%
1Y
−16.0%
From 52W high
−16.7%
From 52W low
+34.8%
$5.09
$8.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
82/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
88
Accruals
85
Issuance
80
Volatility
76
Size
67
Value
65
Growth
50
Momentum
44
Revisions
42

Quality (88): The business earns solid, repeatable profits on what it owns.

Revisions (42): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26INGNHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits +74.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Apr 2026Freedom BrokerInitiatesBuy$12
16 June 2025B. Riley SecuritiesInitiatesBuy—
22 May 2025NeedhamUpgradeBuy—
8 May 2025StifelMaintainsHold—
9 Apr 2025NeedhamReiteratesHold—
27 Feb 2025NeedhamReiteratesHold—
26 Feb 2025NeedhamReiteratesHold—
30 Jan 2025NeedhamReiteratesHold—
14 Jan 2025NeedhamReiteratesHold—
8 Nov 2024NeedhamReiteratesHold—
7 Aug 2024NeedhamReiteratesHold—
8 May 2024NeedhamReiteratesHold—
8 May 2024StifelMaintainsHold—
9 Apr 2024NeedhamReiteratesHold—
15 Feb 2024William BlairUpgradeOutperform—
8 Nov 2023JP MorganMaintainsUnderweight—
8 Aug 2023JP MorganDowngradeUnderweight—
8 Aug 2023StifelMaintainsHold—
14 July 2023NeedhamDowngradeHold—
20 Apr 2023NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Inogen, Inc. returned −16.0% against +12.4% for the S&P 500, dividends included.

INGN vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26INGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Inogen, Inc. (INGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.0×

Cheaper than 93% of US stocks

Price / sales
0.5×

Cheaper than 80% of US stocks

Price / book
1.0×

Cheaper than 68% of US stocks

EV / EBITDA
−11.4×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
3.0%

Higher than 35% of US stocks

Earnings growth (YoY)
3.0%

Higher than 40% of US stocks

Gross margin
45.5%

Higher than 56% of US stocks

Operating margin
−5.1%

Higher than 27% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−13.1%

Higher than 34% of US stocks

Return on assets
−5.8%

Higher than 31% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Inogen, Inc. (INGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inogen, Inc. has a market value of $182.1M and an enterprise value of $92.3M.

  • Revenue in the twelve months to 30 June 2026: $354.3M. The latest quarter grew 3.0% year on year.

  • Net income over the same four quarters: −$24.6M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.90.

  • Free cash flow in the twelve months to 30 June 2026: −$9.7M.

  • Shares outstanding: 26.7M.

  • Trailing P/E: −8.0×; forward P/E: −42.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Inogen, Inc. employs 753 people — $471K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

INGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INGNInogen, Inc.$182.1M82
RXSTRxSight, Inc.$201.6M41
STIMNeuronetics, Inc.$171.4M63
MXCTMaxCyte, Inc.$170.3M91
TLSITriSalus Life Sciences, Inc.$221.3M28
ELMDElectromed, Inc.$225.5M91
LABStandard BioTools, Inc.$237.9M38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INGN news & analysis

Inogen: Cheap Enough To Take A Chance On

Seeking Alpha · 20 Oct 2026positive

Seeking Alpha upgraded Inogen to Buy, citing operational improvements and a robust balance sheet. It noted the $45 million share buyback, debt-free status and cash and investments equal to about 61% of market capitalization, while flagging management turnover and 3% midpoint revenue growth guidance for 2026 as risks.

Why it matters — The article highlights financial resources and signs of operational improvement alongside leadership and growth concerns that may matter to investors following INGN.

Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech

Business Wire · 30 Sept 2026neutral

Inogen announced the divestiture of its U.S. oxygen rental business to Rotech. The announcement was made via a press release from the company's Beverly, Massachusetts location.

Why it matters — INGN watchers would care because the divestiture represents a significant change to the company's U.S. business structure and operations.

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

Zacks Investment Research · 21 Aug 2026neutral

A Zacks Investment Research article discusses why investors should retain Inogen stock, citing portable oxygen concentrator (POC) demand, new products, and international growth as supporting its outlook, while noting U.S. channel shifts and distributor timing as risks.

Why it matters — A Inogen watcher would care because the article highlights the balance of growth drivers and specific risks that could shape the company's near-term performance.

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research notes that Inogen's low valuation and improving margins are offset by weak U.S. sales and rental performance despite strong international demand.

Why it matters — For INGN watchers, the piece highlights the ongoing tension between the company's discounted valuation and the risks posed by its domestic sales challenges.

FAQ

Frequently asked questions about INGN stock

What is the INGN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Inogen, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INGN stock a buy right now?

Of the 2 analysts covering Inogen, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inogen, Inc. 82 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INGN?

As at 31 Oct 2026, Inogen, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).

Will INGN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +74.9% from the last close, and Ticker Nerd's factor model ranks Inogen, Inc. 82 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INGN stock forecast for 2030?

No analyst covering Inogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has INGN stock performed over the past year?

Inogen, Inc. returned -16.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inogen, Inc. do?

Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions.

What is the latest news on INGN?

The most recent item we track (Seeking Alpha, 20 Oct 2026): "Inogen: Cheap Enough To Take A Chance On". Seeking Alpha upgraded Inogen to Buy, citing operational improvements and a robust balance sheet. It noted the $45 million share buyback, debt-free status and cash and investments equal to about 61% of market capitalization, while flagging management turnover and 3% midpoint revenue growth guidance for 2026 as risks.

Company

About Inogen, Inc.

Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions. The company develops, manufactures, and markets portable oxygen concentrators for homecare use, helping patients receive supplemental long-term oxygen therapy in a more mobile form than traditional oxygen systems. Its product portfolio also includes stationary home oxygen concentrators, batteries, accessories, rental offerings, and airway-clearance solutions. Inogen serves patients through direct-to-consumer, business-to-business, and international channels, working with home medical equipment providers, prescribers, and distributors to broaden access to respiratory therapy products. Headquartered in Beverly, Massachusetts, Inogen plays a specialized role in the respiratory health market by addressing everyday oxygen therapy needs across home, travel, and other ambulatory settings.

CEO Mr. Kevin R. M. Smith · 753 employees · United States · https://www.provider.inogen.com